Ultime notizie per SmileDirectClub (OTC:SDCCQ) Azioni

SmileDirectClub Inc is engaged in the orthodontics business. It is mainly involved in the sale of aligners, impression kits, whitening gel, and retainers. The company has one operating segment, aligner products.

SMILEDIRECTCLUB INC A by SmileDirectClub, Inc.

SmileDirectClub Inc

WIIM

TSLA

Tesla shares are trading lower after CEO Elon Musk said he would launch a political party.

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) will release earnings results for the second quarter, before the opening <a href="https://www.benzinga.com/quote/JPM/earnings">bell on Tuesday, July 15.</a>
Analysts expect the New York-based company to report quarterly earnings at $4.47 per share, down from $6.12 per share in the year-ago period. JPMorgan projects to report quarterly revenue of $43.98 billion, compared to $50.2 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 1, JPMorgan announced a dividend increase and authorized a new buyback. The company's board announced that it intends to increase the quarterly stock dividend from $1.40 per share to $1.50 per share for the third quarter.
JPMorgan shares gained 1.9% to close at $296.00 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/jpm/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating and raised the price target from $280 to $298 on July 2, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Keith Horowitz maintained a Neutral rating and boosted the price target from $250 to $275 on June 26, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Morgan Stanley analyst Betsy Graseck maintained an Equal-Weight rating and boosted the price target from $236 to $240 on June 23, 2025. This analyst has an accuracy rate of 61%.</li>
<li>B of A Securities analyst Ebrahim Poonawala maintained a Buy rating and raised the price target from $300 to $325 on June 18, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Wells Fargo analyst Mike Mayo maintained an Overweight rating and boosted the price target from $300 to $320 on June 10, 2025. This analyst has an accuracy rate of 70%</li>
</ul>
Considering buying JPM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/JPM/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-1024x586.png" alt="" class="wp-image-974060" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

JPMorgan Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">EPWK Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPWK#NASDAQ">EPWK</a>)</h3>
<ul class="wp-block-list">
<li>On May 27, EPWK Holdings posted a H2 loss of 3 cents per share. The company's stock fell around 15% over the past month and has a 52-week low of $0.41.</li>
<li>RSI Value: 24.5</li>
<li>MKZR Price Action: Shares of EPWK Holdings fell 3.3% to close at $0.50 on Thursday.</li>
<li>Edge Stock Ratings: Value at 35.23. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/EPWK"><img loading="lazy" decoding="async" width="408" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070633/image-56.png" alt="" class="wp-image-974564" style="width:291px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070633/image-56.png 408w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070633/image-56-300x134.png 300w" sizes="(max-width: 408px) 100vw, 408px" /></a></figure>
<h3 class="wp-block-heading">HUYA Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>)</h3>
<ul class="wp-block-list">
<li>On May 13, HUYA posted first-quarter adjusted earnings of 1 cent per share. Mr. Junhong Huang, Acting Co-Chief Executive Officer and Senior Vice President of Huya, commented, &#8220;During the first quarter of 2025, we continued to strengthen our live streaming content ecosystem, deepen collaborations with game companies and content platforms, and effectively implement our strategic business transformation.&#8221; The company's stock fell around 40% over the past month and<a href="https://www.benzinga.com/quote/HUYA"> has a 52-week low</a> of $0.080.</li>
<li>RSI Value: 26.1</li>
<li>HUYA Price Action: Shares of HUYA closed at $2.47 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707">HUYA stock</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707"><img loading="lazy" decoding="async" width="920" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57.png" alt="" class="wp-image-974568" style="width:710px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57-768x694.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Gibo Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>)</h3>
<ul class="wp-block-list">
<li>On June 30, GIBO Holdings announced the successful testing of its AI-driven engine, GIBO Click, on uDrama, a rising star in the global short drama landscape.. The company's stock fell around 96% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/GIBO">low of $0.082</a>.</li>
<li>RSI Value: 10.1</li>
<li>GIBO Ltd Price Action: Shares of Gibo Holdings dipped 29.6% to close at $0.084 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707">RETO shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707"><img loading="lazy" decoding="async" width="882" height="806" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58.png" alt="" class="wp-image-974576" style="width:673px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58.png 882w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58-768x702.png 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

EPWK

GIBO

HUYA

Top 3 Tech And Telecom Stocks That Are Set To Fly In Q3

<ul>
<li>Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population.</li>
<li>Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo.</li>
<li>Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use in this patient population.</li>
<li>Bezuclastinib NDA submission to FDA expected by end of 2025; strong financial position with $237 million current cash balance and access up to an additional $350 million via recently announced debt facility with SLR Capital Partners.</li>
<li>On track to share pivotal trial results from PEAK in GIST and APEX in AdvSM in 2H 2025</li>
</ul>

Biotech

Health Care

General

COGT

Cogent Biosciences Announces Topline Results From Part 2 Of The SUMMIT Trial Of Bezuclastinib For Non-advanced Systemic Mastocytosis, Demonstrating Clinically Meaningful And Highly Statistically Significant Improvements Across The Primary And All Key Secondary Endpoints

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox
TNX-801 confers durable protection after a single dose
TNX-801 is well tolerated in immunocompromised animals, without evidence of spreading to blood or tissues even at high doses
CHATHAM, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) ("Tonix" or the "Company"), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Sina Bavari, PhD, Executive Vice President of Infectious Disease Research and Development at Tonix Pharmaceuticals, will present new data on TNX-801 (recombinant horsepox virus, live vaccine) at the upcoming Vaccine Congress 2025.
TNX-801 is a minimally replicative, attenuated live virus vaccine candidate designed to generate durable humoral and cellular immunity after a single dose. Preclinical results in animals have demonstrated protection against mpox and other orthopoxviruses, supporting further clinical evaluation. TNX-801 also serves as an orthopoxvirus vaccine platform that can deliver multiple protective antigens against diverse viral pathogens.
Dr. Bavari will present the safety, immunogenicity, and efficacy findings to date and describe Tonix's plans to advance the TNX-801 platform into clinical trials to protect against mpox and other viral diseases.

TNXP

Tonix Pharma To Present New Data On TNX-801, Recombinant Horsepox Virus, Live Vaccine, At Upcoming Vaccine Congress 2025

The Joint Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>), the nation's largest franchisor of chiropractic care through The Joint Chiropractic&#xAE; network, closed the sale of 31 corporate owned and managed clinics and associated franchise licenses in Arizona and New Mexico to Joint Ventures, LLC in exchange for $8.3 million in cash and the regional developer (RD) territory rights of the Northwest region that generated $855,000 in royalties and franchise fees over the 12 months ended March 31, 2025. "Our goal for the refranchising initiative is to strengthen and simplify our business, while ensuring our clinics go to proven franchise operators that can improve performance and grow within their regions," said The Joint Corp.'s President, Chief Executive Officer and Director Sanjiv Razdan. "We are very happy that Joint Ventures, one of our strongest franchisees, is purchasing 31 clinics in Arizona and New Mexico. As part of the consideration for the clinics, we are acquiring Joint Ventures' regional developer rights for the Northwest region, covering 46 existing franchised clinics and 30 sites for future clinic development. By acquiring RD rights, we will reduce commission obligations and increase operating margin, as these clinics incurred $855,000 in royalties and commissions under these RD rights in the trailing twelve months ended March 31, 2025. By increasing their stake in The Joint, existing franchisees are validating our initiatives to strengthen the patient experience, drive revenue and reduce operational costs. We expect to deploy our expanding working capital to generate value for stockholders."

JYNT

The Joint Sells 31 Clinics for $8.3M, Gains Control of Profitable Northwest Franchise Region

Heidmar Maritime Holdings Corp. (the "Company" or "Heidmar") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMR#NASDAQ">HMR</a>) today announces its first vessel acquisition, making it a strategic milestone in the Company's project development and growth strategy.
Heidmar has entered into an agreement to acquire C/V A. Obelix, a 1,702 TEU cellular/gearless feeder container vessel, built in 2008 at Wadan/Aker Yards, Wismar Germany. C/V A. Obelix is classed by Lloyd's Register and has been strengthened for Ice Class II operations. The vessel is powered by a two-stroke main engine and is equipped with a bow thruster, allowing for a high degree of maneuverability and independence in port operations, and a high-capacity 330-plug reefer system. The vessel's next drydock is scheduled for 2028 allowing for three clear years of operations with no projected upfront maintenance expense.
Heidmar is acquiring its interest in the vessel from a related party at an aggregate purchase price of $25.25 million. The security of the charter revenue and the end-of-life recycling price are expected to effectively cover the cost of the acquisition in case of the high EBITDA scenario.

Heidmar Maritime Agrees To Acquire Cellular/Gearless Feeder Container Vessel, C/V A. Obelix, For $25.25M

Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm", or the "Company") (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sand#NYSE">SAND</a>) (TSX:SSL) is pleased to announce that the Company has entered into a definitive arrangement agreement with Royal Gold Inc.
Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm", or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SSL#TSX">SSL</a>) is pleased to announce that the Company has entered into a definitive arrangement agreement with Royal Gold Inc. ("Royal Gold"), pursuant to which Royal Gold will acquire all of the issued and outstanding common shares of Sandstorm (the "Sandstorm Shares") in an all-share transaction with an implied value of approximately $3.5&nbsp;billion (the "Sandstorm Transaction"). Sandstorm shareholders will receive 0.0625 of a share of common stock of Royal Gold (each whole share, a "Royal Gold Share") for each Sandstorm Share held, implying a 21% premium to the 20-day volume-weighted average price ("VWAP") of the Sandstorm Shares for the period ended July 3, 2025, and a 17% premium to the closing price of the Sandstorm Shares on the New York Stock Exchange (the "NYSE") on July 3, 2025. Upon closing, existing Royal Gold and Sandstorm shareholders will own approximately 77% and 23%, of the issued and outstanding Royal Gold Shares on a fully diluted basis.

RGLD

SAND

Sandstorm Gold Enters Agreement With Royal Gold, Under Which Royal Gold Will Acquire All Issued And Outstanding Shares Of Sandstorm In All-Share Deal With Implied Value Of $3.5B

NTRA

Natera Highlights Clinical Results From CIRCULATE-Japan Study, Demonstrating Latitude MRD Assay's Prognostic And Predictive Value

LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, intended to enable earlier patient access to therapies with expedited clinical development timelines.

LXEO

The FDA Grants Breakthrough Therapy Designation To Lexeo Therapeutics' LX2006 Based On Clinical Evidence Generated On Both Cardiac And Neurologic Measures Of Friedreich Ataxia

The FDA Approves Expanding The Instructions For Use Labeling For Boston Scientific's Farapulse Pulsed Field Ablation System To Include Approval For The System For Drug-refractory, Symptomatic Persistent Atrial Fibrillation

CRGO

SEKO Logistics Expands Freightos Integration To Unify Global Air And Ground Quoting And Booking Workflows

<a href="https://www.globenewswire.com/Tracker?data=xcP7wf83V4GEKHc3LIsF5CN7ExOTRlN2vdGpSbVRyRF1wxXQcbFUUUf0r3adWNQWJrYRos-xPecs45_LouQic97ZEDik3Cj2_ZVnXTh4QV0=">BeyondSpring Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) today announced publication of a human clinical study in&nbsp;Med&nbsp;(Cell Press) demonstrating that Plinabulin, when combined with radiation and a checkpoint inhibitor, induces dendritic cell (DC) maturation and elicits tumor responses in patients across multiple cancer types who had failed prior ICI therapy. The study also identified a potential biomarker—baseline GEF-H1 immune signature—that may enable patient pre-selection and clinical response prediction.
"These results offer early but important signals that Plinabulin's dendritic cell maturation mechanism could play a pivotal role in reversing ICI-acquired resistance," said Dr. Steven Lin, M.D., Ph.D., corresponding author and Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center. "The ability of Plinabulin to activate the immune system in this setting is both scientifically intriguing and clinically promising—particularly given the durability of responses in some heavily pretreated patients."
Dr. Lin added, "It is especially noteworthy that Plinabulin combination demonstrated the best responses in non-small cell lung cancer, head and neck squamous cell carcinoma, and Hodgkin lymphoma."
"This study builds upon the seminal work of Nobel Laureate Dr. Ralph Steinman and Dr. Ira Mellman, who helped define the essential role of dendritic cells in immune activation," said Lan Huang, Ph.D., Co-Founder, Chairman, and CEO of BeyondSpring. "Plinabulin's ability to drive dendritic cell maturation and induce immune responsiveness offers a potential breakthrough strategy for patients who are refractory or relapsed on checkpoint inhibitors. We are committed to advancing Plinabulin's development in partnership with pioneering cancer research institutions like MD Anderson."
Triple I/O Combination Study Highlights
This investigator-initiated, Phase 1 translational trial (NCT04902040) evaluated a triple immunotherapy approach combining Plinabulin, radiation (RT), and anti-PD-1 checkpoint inhibitors in patients with eight cancer types who are refractory or relapsed on prior ICI therapy. RT was administered only during the first cycle. The primary endpoint was tumor response in non-irradiated lesions.
<ul>
<li>Clinical Results Nineteen patients received the combination regimen—14 on pembrolizumab and 5 on nivolumab. Tumor responses were evaluable in 13 ICI-relapsed patients across eight tumor types. Objective response rate (ORR) was 23%, and disease control rate (DCR) was 54%. Clinically meaningful benefits (PR, partial response; SD, stable disease) were observed in NSCLC (2/2), HNSCC (2/3), and Hodgkin lymphoma (2/2). Both Hodgkin lymphoma patients had durable responses exceeding 19 months despite 12–16 prior lines of therapy.</li>
<li>Mechanism Confirmation Plinabulin triggered DC maturation post-RT via GEF-H1 signaling. Flow cytometry of whole blood revealed increased expression of DC maturation markers (CCR7, CD80, CD83) and a shift in monocyte subpopulations from classical to proinflammatory phenotype in responders.</li>
<li>Biomarker Insight Single-cell RNA sequencing differentiated responders from non-responders and identified baseline GEF-H1 immune gene expression as a potential predictive biomarker for Plinabulin response. &nbsp;</li>
</ul>

BYSI

BeyondSpring Drug Triggers Immune Response in Patients Who Failed Prior Cancer Immunotherapy

BlackRock To Acquire ElmTree Funds; ElmTree Funds Has $7.3B In Total AUM As Of Mar. 31

First of three projects with APS now in operation, delivering flexible capacity to the grid
KITCHENER, ON, July 7, 2025 /PRNewswire/ -- <a href="https://recurrentenergy.com/">Recurrent Energy</a>, a subsidiary of <a href="https://www.canadiansolar.com/">Canadian Solar Inc.&nbsp;</a>("Canadian Solar") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>), and a leading global developer, owner, and operator of solar and energy storage assets, announced today that the 1,200 MWh Papago Storage facility in Maricopa County, Arizona, has reached commercial operation. The project is now dispatching stored energy to Arizona Public Service (APS), the state's largest electric utility, in time to help meet rising electricity demand during the summer season.

CSIQ

Canadian Solar's Recurrent Energy Says 1,200 MWh Papago Storage Facility In Maricopa County, Arizona, Reaches Commercial Operation

Management

BCRX

BioCryst Pharmaceuticals Appoints Babar Ghias As Chief Financial Officer And Head Of Corporate Development

NRIX

Nurix Therapeutics Granted Orphan Drug Designation By European Medicines Agency For Bexobrutideg In Waldenström Macroglobulinemia

Descartes Systems Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DSG#TSX">DSG</a>), the global leader in uniting logistics-intensive businesses in commerce, announced the release of Descartes MacroPoint&#x2122; FraudGuard 2.0, the latest advancement in freight fraud technology designed to help shippers, freight brokers, and third-party logistics providers (3PL) safeguard their business against increasingly sophisticated fraud and cargo theft schemes. With new capabilities for pre-tender, pre-pickup and in-transit shipments, companies can maintain a high-performing, compliant carrier network, enhance the reliability of critical decision-making insights, and better detect and mitigate potential identity fraud or double brokering to avoid insurance, liability, and reputational risks.&nbsp;

DSGX

TSX:DSG

Descartes Systems Releases Descartes MacroPoint FraudGuard 2.0 To Provide Transportation Industry With Next-Gen Solution For Freight Fraud Defense

The Wall Street Journal Reported BlackRock Has Agreed To Acquire ElmTree Funds

Oracle Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) has declared a significant reduction in&nbsp;its database software and cloud-computing&nbsp;service prices for the federal government
What Happened: Oracle is offering a 75% discount on its license-based software — including databases and analytics tools — to government agencies. Additionally, the company is offering a &#8220;substantial&#8221; discount on its cloud service until the end of November, as stated by the General Services Administration (GSA), <a href="https://www.wsj.com/articles/oracle-gives-u-s-government-discount-on-cloud-and-software-9d893fc4?reflink=desktopwebshare_permalink&amp;st=kuMQUR&amp;">detailed</a> by The Wall Street Journal.
The GSA, which handles procurement for the federal government, revealed that its agreement with Oracle is the first of its kind to provide a government-wide discount on cloud infrastructure. The agency is also in talks with other cloud providers to explore the possibility of securing similar agreements.
Oracle's agreement also includes granting the federal government access to its AI services and offering specialized support for migrating IT systems to the cloud. Traditionally recognized for its database software, the company has recently expanded its government collaborations, launching a new program last month to help smaller vendors sell technology to the Defense Department.
The GSA aims to achieve these savings by negotiating directly with tech companies and bypassing third parties. The agency anticipates securing longer-term discounts with tech providers in the near future.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/politics/25/07/46268640/china-expresses-concern-to-eu-over-russias-potential-defeat-in-ukraine-conflict-amid-fears-that-tru" target="_blank" rel="noreferrer noopener">China Expresses Concern To EU Over Russia&#8217;s Potential Defeat In Ukraine Conflict Amid Fears That Trump Would Do &#8216;This&#8217;: Report</a>
Why It Matters: Oracle&#8217;s recent move aligns with its <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46248645/oracle-shares-soared-higher-over-the-past-month-whats-going-on">strong performance </a>over the past month, as the company&#8217;s shares soared by more than 30%. The company kicked off June with robust fourth-quarter earnings, surpassing estimates.
Oracle&#8217;s CEO, Safra Catz, noted a &#8220;strong start&#8221; to fiscal 2026, <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46171946/oracle-stock-hits-all-time-high-after-ceo-flags-strong-start-to-fiscal-2026">with the </a>company&#8217;s MultiCloud database revenue experiencing over 100% growth. This growth trajectory, coupled with Oracle&#8217;s strategic edge in the global AI race, may have influenced the company&#8217;s decision to offer these unprecedented discounts to the U.S. government.
During its fourth quarter earnings results, Oracle&#8217;s Chairman, Larry Ellison, highlighted the company&#8217;s <a href="https://www.benzinga.com/markets/earnings/25/06/45909157/larry-ellison-says-most-of-the-worlds-valuable-data-is-in-oracle-as-ai-demand-skyrockets">competitive strength</a> in its deep integration inside enterprise data architecture, a factor that allows it to compete successfully against other giants in the AI space.
On a year-to-date basis, oracle stock surged 42.94%, as per <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/tech/25/07/46204491/microsofts-ai-and-cloud-scale-drives-market-beating-returns">Microsoft&#8217;s AI And Cloud Scale Drives Market-Beating Returns</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments

SmileDirectClub

Notizie

Ultime notizie per SmileDirectClub (OTC:SDCCQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO